These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 24200404

  • 21. RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study.
    Tripp CS, Cuff C, Campbell AL, Hendrickson BA, Voss J, Melim T, Wu C, Cherniack AD, Kim K.
    Adv Ther; 2017 Jun; 34(6):1364-1381. PubMed ID: 28455782
    [Abstract] [Full Text] [Related]

  • 22. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K.
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [Abstract] [Full Text] [Related]

  • 23. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.
    Kulus M, Hébert J, Garcia E, Fowler Taylor A, Fernandez Vidaurre C, Blogg M.
    Curr Med Res Opin; 2010 Jun; 26(6):1285-93. PubMed ID: 20377320
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma.
    Barnes N, Pavord I, Chuchalin A, Bell J, Hunter M, Lewis T, Parker D, Payton M, Collins LP, Pettipher R, Steiner J, Perkins CM.
    Clin Exp Allergy; 2012 Jan; 42(1):38-48. PubMed ID: 21762224
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis.
    Papp K, Menter A, Strober B, Kricorian G, Thompson EH, Milmont CE, Nirula A, Klekotka P.
    J Am Acad Dermatol; 2015 Mar; 72(3):436-439.e1. PubMed ID: 25553889
    [Abstract] [Full Text] [Related]

  • 28. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
    Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS.
    Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
    [Abstract] [Full Text] [Related]

  • 29. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.
    Busse WW, Wenzel SE, Meltzer EO, Kerwin EM, Liu MC, Zhang N, Chon Y, Budelsky AL, Lin J, Lin SL.
    J Allergy Clin Immunol; 2013 Feb; 131(2):339-45. PubMed ID: 23174659
    [Abstract] [Full Text] [Related]

  • 30. Inhaled corticosteroids in children with persistent asthma: effects on growth.
    Zhang L, Prietsch SO, Ducharme FM.
    Evid Based Child Health; 2014 Dec; 9(4):829-930. PubMed ID: 25504972
    [Abstract] [Full Text] [Related]

  • 31. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma.
    Parker JM, Oh CK, LaForce C, Miller SD, Pearlman DS, Le C, Robbie GJ, White WI, White B, Molfino NA, MEDI-528 Clinical Trials Group.
    BMC Pulm Med; 2011 Feb 28; 11():14. PubMed ID: 21356110
    [Abstract] [Full Text] [Related]

  • 32. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G.
    Respir Med; 2008 Oct 28; 102(10):1371-8. PubMed ID: 18657960
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H, Orozco S, Allen A.
    Clin Ther; 2012 Aug 28; 34(8):1683-95. PubMed ID: 22796247
    [Abstract] [Full Text] [Related]

  • 34. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma.
    Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, Holgate ST, Meyers DA, Rabe KF, Antczak A, Baker J, Horvath I, Mark Z, Bernstein D, Kerwin E, Schlenker-Herceg R, Lo KH, Watt R, Barnathan ES, Chanez P, T03 Asthma Investigators.
    Am J Respir Crit Care Med; 2009 Apr 01; 179(7):549-58. PubMed ID: 19136369
    [Abstract] [Full Text] [Related]

  • 35. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma.
    Berger W, Gupta N, McAlary M, Fowler-Taylor A.
    Ann Allergy Asthma Immunol; 2003 Aug 01; 91(2):182-8. PubMed ID: 12952113
    [Abstract] [Full Text] [Related]

  • 36. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma.
    Kishiyama JL, Valacer D, Cunningham-Rundles C, Sperber K, Richmond GW, Abramson S, Glovsky M, Stiehm R, Stocks J, Rosenberg L, Shames RS, Corn B, Shearer WT, Bacot B, DiMaio M, Tonetta S, Adelman DC.
    Clin Immunol; 1999 May 01; 91(2):126-33. PubMed ID: 10227804
    [Abstract] [Full Text] [Related]

  • 37. Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study.
    Kim TH, Kishimoto M, Wei JC, Jeong H, Nozaki A, Kobayashi S.
    Rheumatology (Oxford); 2023 May 02; 62(5):1851-1859. PubMed ID: 36130275
    [Abstract] [Full Text] [Related]

  • 38. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.
    Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, Danzig M, Cuss F, Pauwels RA.
    Am J Respir Crit Care Med; 2003 Jun 15; 167(12):1655-9. PubMed ID: 12649124
    [Abstract] [Full Text] [Related]

  • 39. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial.
    Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, Fabbri LM, Rabe KF.
    Lancet Respir Med; 2013 Mar 15; 1(1):23-31. PubMed ID: 24321801
    [Abstract] [Full Text] [Related]

  • 40. A randomized, double-blind trial of the effect of treatment with formoterol on clinical and inflammatory parameters of asthma in children.
    Stelmach I, Gorski P, Jerzynska J, Stelmach W, Majak P, Kuna P.
    Ann Allergy Asthma Immunol; 2002 Jul 15; 89(1):67-73. PubMed ID: 12141723
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.